Regulatory watch: FDA new drug approvals in Q1 2018

Nature Reviews Drug Discovery 17, 309 (2018). doi:10.1038/nrd.2018.61 Author: Lisa Urquhart The first quarter of the year saw two notable FDA approvals for HIV therapies. In early February, Gilead Sciences gained approval for its triple combination product Biktarvy, which brings together the novel HIV-1 integrase inhibitor bictegravir with the established dual nucleoside reverse transcriptase inhibitor (NRTI)
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research